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Table 1
Patient Characteristics
No CRT CRT +
Anticoagulation
CRT with no
anticoagulation
Number of patients 190 11 13
Median age at transplant
(year)
58 62 60
Male gender 116 6 10
Ethnicity:
Caucasian 122 7 12
African 47 2 1
Asian 7 0 0
Hispanic 6 2 0
Other/Unknown 8 0 0
Malignancy:
Myeloma 132 8 8
Non-Hodgkin’s lymphoma 34 2 3
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Introduction: Pain following hematopoietic stem cell
transplantation (HSCT) is caused by several factors: chemo-
therapy, radiotherapy, infections, GVHD, and medications.
Difﬁculties in deﬁning and accurately diagnosing pain
symptoms can lead to delays in starting effective analgesia
and poorer quality of life. Pain syndromes following HSCT
have not been well-studied and the actual prevalence is
unknown. The goal of this study was to determine incidence,
severity, and the time course of pain following HSCT.
Method: We designed a prospective, observational study
which enrolled 100 patients undergoing HSCT (60%
autologous, 40% allogeneic. 19 unrelated, 13 sibling, 8 double
cord. Myeloma 44%, leukemia 29%, lymphomas 26%, and
aplastic anemia 1%). Patients enrolling on the study
completed 5 questionnaires before HSCT and 1, 2, 3, 6, 9,
and 12 months after HSCT. The questionnaires were the
Brief Pain Inventory (BPI), the EORTC Quality of Life
Questionnaire-Chemotherapy Induced Peripheral Neuropa-
thy (EORTC-CIPN), the Muscle and Joint Measure (MJM), the
MD Anderson Symptom Index e Graft-versus-Host Disease
module (MDASI-cGVHD), and the Hospital Anxiety and
Depression Scale (HADS).
Results: At the 9-month review, we found that there was a
signiﬁcant increase in pain reported after allogeneic HSCT
compared to pre-HSCT. (71% increase at 3 months; p¼0.01).
This difference was independent of conditioning regimen,
disease or GVHD. For autologous HSCT, there was an increase
in reported neuropathic symptoms (47% increase at 3
months; p¼0.02). We also found and increase in muscle
cramping and spasms late after HSCT; both autologous and
allogeneic (99% increase at 9 months; p¼0.03). Muscle
cramping interfered with sitting, standing and physical
activity (21% at 6 months; p¼0.04 and 136% at 9 months;
p¼0.04). The increase in muscle cramping symptoms was
independent of conditioning regimen, disease or GVHD.
Conclusions: Our current review of this study reveals that
pain and muscle cramping is a signiﬁcant symptom that
develops after both allogeneic and autologous HSCT. This
appears to be independent of conditioning regimen, disease
or GVHD.Hodgkin’s lymphoma 12 0 0
Primary amyloidosis 3 1 2
CLL 2 0 0
AML 2 0 0
APML 1 0 0
Other 4 0 0
Conditioning:
Melphalan alone 135 9 10
BEAM 48 2 3
Busulfan/Cyclophosphamide 2 0 0
Cyclophosphamide alone 4 0 0
Unknown 1 0 0
Neutrophil engraftment
(in days)
11 12 12
Platelet engraftment
(in days)
15 17 17
Table 2
Outcome analysis
No CRT CRT +
Anticoagulation
CRT with no
anticoagulation
p-
value
Platelet utilization
(Number of pooled
platelet units)
4 14 4 0.02
PRBC cell utilization
(Number of PRBC
transfusions)
2 4 2 0.01346
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Introduction: The optimal management of catheter-related
thrombosis (CRT) in patients undergoing autologous
stem-cell transplantation (ASCT) remains poorly deﬁned. We
reviewed the management of catheter-related thrombosis in
ASCT patients in our transplant unit over an 8-year period.Methods: We reviewed all patients undergoing ASCT at
Thomas Jefferson University from 2006-2013. Patients with
previous history of venous thrombosis receiving anti-
coagulation at ASCT were excluded. Patients with CRT were
identiﬁed andmanagementwas reviewed. Three populations
were identiﬁed: No CRT, CRT no anticoagulation, and CRT on
anticoagulation. We performed a Wilcoxon Ranks Sum anal-
ysis to evaluate blood and platelet utilization in the three
groups. We also reviewed major bleeding events (MBE) and
secondary thrombotic events (pulmonary embolism, PE).
Results: We identiﬁed 214 patients as described in Table 1.
The incidence of CRT for the whole group was 11.2%. Of the
24 patients with CRT, 46% were treated with AC and the
remaining was observed without AC. The median number of
pooled platelets transfused was 14 in the CRT + AC group, 4
in the no CRT and 4 CRT with no anticoagulation groups
(p¼0.02). The median number of PRBC transfusions in the
no CRT, CRT + AC, and CRT with no AC groups was, 2, 4, and
2, respectively (p¼0.01). None of the patients with CRT
developed a second thrombotic event (PE). Incidence of
major bleeding within the CRT + AC group was 27% while in
the CRT and no AC group was 15% (p¼NS). One patient
expired due to the result of a subarachnoid hemorrhage.
Conclusions: A strategy utilizing AC for CRT in the setting of
an autologous transplant results in increased utilization of
both platelet and PRBC transfusion and is associated with a
trend towards a higher risk of major bleeding. There was no
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S251difference in the incidence of PE following CRT in patients
treated with or without AC in this small cohort of ASCT
patients.347
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Purpose: Invasive fungal infections are becoming increas-
ingly prevalent, particularly in the immunocompromised
population. The development of new antifungal agents with
novel mechanisms of action has sparked interest in
combination antifungal therapies. This study seeks to
characterize combination antifungal use at a large academic
health system.
Methods: We conducted a retrospective observational study
of adult inpatients with the intent of characterizing
combination systemic antifungal utilization between the
dates of July 1, 2012 and June 30, 2013. Combination
antifungal therapy was deﬁned as administration of two or
more target systemic antifungals (liposomal amphotericin B,
ﬂuconazole, voriconazole, posaconazole, micafungin or
terbinaﬁne) for ﬁve or more days.
Results: Twenty nine patients received combination
antifungal therapy and 36 unique treatment courses were
identiﬁed. Ten of the 29 patients (35%) were BMT patients.
Pneumoniawas themost common disease indication (20/29;
69%). Unknown was the most common organism indication
overall (11/29; 38%) and within the BMT patient population
(6/10; 60%). Among the 36 unique treatment courses the
most common combination therapy by drug class was an
azole and an echinocandin (53%; 19/36) followed by a
polyene and an azole (31%; 11/36).
Conclusion: A signiﬁcant proportion of the study popula-
tion both overall (35%) and among BMT patients (60%)
received combination antifungal therapy with no identiﬁed
infecting fungal organism. There is no data to support such
a practice. However, in the setting of severe invasive fungal
infections, particularly in immunocompromised hosts, us-
ing additional antifungal agents may seem less risk-prone
than invasive diagnostics like tissue biopsy. These ﬁndings
suggest that earlier diagnostic methods including tissue
biopsy are warranted to avoid unnecessary use of combi-
nation antifungal therapy when no pathogen has been
identiﬁed.348
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Background: Linezolid is effective against drug-resistant
Gram-positive bacteria, and has been widely used for the
treatment of various infectious diseases due to such bacteria.
Although linezolid has a favorable safety proﬁle, myelosup-
pression is one of its clinically important toxicities.
Myelosuppression due to linezolid has not beensystematically evaluated in the setting of hematopoietic stem
cell transplantation (HSCT). Therefore, effect of linezolid
administration on the myeloid engraftment after allogeneic
HSCT was retrospectively evaluated.
Patients and Methods: Patients in whom intravenous or
oral linezolid (1200 mg/day) administration was initiated
before myeloid engraftment following allogeneic HSCT
and continued for 5 days or longer were selected from
the institutional database. The patient characteristics,
duration of linezolid treatment, and myeloid engraftment
were retrospectively evaluated by using the medical
records.
Results: Fifteen patients were evaluable and enrolled into
the analysis. All patients were male, and median age at
transplant was 50 years (range, 21e60). Underlying diseases
were acute leukemia in 11 patients, myelodysplastic
syndrome in 2, and myeloproliferative neoplasm and
malignant lymphoma each in 1. All but 1 received myeloa-
blative conditioning. Stem cell sources were bone marrow
from related or unrelated donor in 10 patients, cord blood in
3, and peripheral blood stem cell (PBSC) in 2. Linezolid was
initiated at a median of 12.5 days after HSCT (range, -3e20),
whose median duration of treatment was 14 days (range,
5e20). Although all patients achieved myeloid engraftment
(absolute neutrophil exceeding 0.5 x 109/L), the median day
of engraftment was 22.5 days after HSCT (range, 12e33).
Japanese national registry data showed that the median days
of myeloid engraftment were 12 days and 14 days after
allogeneic PBSCT and BMT, respectively (Nagafuji K, et al. Int J
Hematol 2010). In 8 (53%) of 15 patients, myeloid engraft-
ment was achieved later than 21 days after engraftment.
Conclusion: Although myeloid engraftment was achieved,
the engraftment was considered delayed in patients who
received linezolid early after allogeneic HSCT. Although the
number of subjects evaluated was small, these results
suggest that linezolid could have a potential to delay
neutrophil recovery, and should be carefully used after
allogeneic HSCT.349
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Background: Posaconazole (PCZ) delayed-release (DR)
tablets were FDA approved in late 2013 for prophylaxis of
invasive fungal infections (IFI). In 3 clinical studies leading to
approval, PCZ DR exhibited signiﬁcant pharmacokinetic
advantages over oral suspension (OS), largely due to
improved absorption. Historically, subtherapeutic PCZ OS
levels were linked with breakthrough IFI. We aim to evaluate
PCZ DR serum levels in the bone marrow transplant (BMT)
population and link levels to IFI breakthrough prevention
and treatment.
Methods: After approval by Pharmacy and Therapeutics, PCZ
levels were routinely obtained in BMT patients18 years old
started on PCZ DR. A retrospective chart review was
performed between January 1 and June 30, 2014. Baseline
demographics, PCZ dose and levels, as well as patient speciﬁc
factors with the potential to affect levels and development of
IFIs were collected.
